Saturday 7 November 2026 Export CCEL’s income statement to Excel — free account

Cryo-Cell International Inc.

Cryo-Cell International Inc.’s revenue for fiscal 2025 (year ended November 2025) was $31.6 million, down 1.31% from fiscal 2024.

Revenue: −0.02%
EPS: +77.8%
Free cash flow: −58.4%
Total debt: −29.5%

Quarter to August 2026, against a year earlier

4.97 0.02 +0.40%

Follow CCEL

Alert me

Market cap: $39.9M
P/E: 0.0×
Fwd P/E: 65.1×
Dividend yield: 0.00%
F-score: 6/9
Altman Z: −0.23
Beneish M: −3.17
Dividend safety: 20/100

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 47.91%

Capital & Financial Ratios $m

Size

Market Cap 39.91

Revenue ttm 31.13

Net income ttm (1.95)

Free cash flow ttm 4.65

Net debt Q 3.81

Valuation

P/E 0.00

Forward P/E 65.10

Price / sales 1.29

Forward P/S Powerpack

Price / FCF 12.58

Price / book 0.00

Financial health

Current ratio Q 0.86

Debt / equity Q (0.49)

Interest coverage Q 5.01

Growth

Revenue growth Q −0.02%

Operating income growth Q +15.43%

EPS, this year +136.67%

EPS, next year A −81.82%

Revenue, next year A −4.84%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.72%

10-year low 10-year high

EV/Sales against its own 10 years 21.22%

10-year low 10-year high

EV/FCF against its own 10 years 81.18%

10-year low 10-year high

Dividends

Yield: 0.00%
Annual rate: 0.00
Payout ratio: —
Growth, 2024–25: +60.0%/yr

0.25 ’24
0.40 ’25 +60

paid change on the year, %

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1	3	3	4
Receivables	7	7	7	7
Inventory	1	1	0	1
Other	1	0	1	1
	9	13	12	13

	2023	2024	2025	Q'26
Payables	3	2	3	2
ST’ Debt	1	4	2	—
Other	1	—	—	—
	21	22	20	15

Compound Annual Growth %

	10y	5y	3y
Sales	4.11%	0.27%	1.33%
Cash Flow	1.22%	(8.34%)	(13.86%)
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

EPS $

	Feb	May	Aug	Nov	Year
’26	0.01	0.07	0.16	—	—
’25	0.03	0.04	0.09	(0.47)	(0.30)
’24	0.07	0.08	0.13	(0.23)	0.05
’23	0.09	0.03	0.08	(1.34)	(1.14)
’22	0.10	0.07	0.06	0.10	0.33
’21	0.08	0.14	0.10	(0.08)	0.25
’20	0.08	0.12	0.10	0.15	0.45

Fiscal quarters ending in the months shown.

Revenue $m

	Feb	May	Aug	Nov	Year
’26	8	8	8	—	—
’25	8	8	8	8	32
’24	8	8	8	8	32
’23	8	8	8	8	31
’22	7	8	8	8	30
’21	7	7	8	7	29
’20	8	8	8	8	31

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	1	2	1	—	—
’25	1	1	3	1	5
’24	0	2	2	2	6
’23	2	2	2	3	9
’22	2	2	3	2	9
’21	3	2	2	2	8
’20	3	1	2	3	8

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	1	2	1	—	—
’25	1	1	2	1	5
’24	(1)	(1)	2	2	2
’23	1	0	(1)	1	1
’22	(4)	2	(9)	4	(7)
’21	3	(3)	1	1	1
’20	3	1	2	3	8

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Aug ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	23	25	29	32	31	29	30	31	32	32	31		+3.5%	30	28	—	(5.1%)
	Gross margin, %	75.03	73.51	70.77	68.46	68.99	68.88	71.02	73.23	75.15	76.63	78.54		+1.6 pt	Powerpack Cryo-Cell International Inc.’s next three years, line by line Analysts expect revenue to shrink 5.1% a year to 2028 — slower than the 3.5% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(2)	4	4	3	5	3	3	(13)	3	(2)	(2)		(0.7%)
	EBT margin, %	(10.72)	14.28	12.38	10.66	16.18	9.04	10.94	(42.64)	8.77	(7.40)	(6.13)		+3.3 pt
	Net income	(1)	2	(1)	2	4	2	3	(10)	0	(2)	(2)		+7.0%
Per share, $
Per share, $	Revenue	2.85	3.59	3.92	4.08	4.13	3.55	3.58	3.76	3.93	3.91	3.86		+3.6%
	Earnings	(0.16)	0.33	(0.11)	0.29	0.45	0.26	0.33	(1.14)	0.05	(0.30)	(0.23)		+7.2%
	Cash flow	0.61	0.81	0.71	0.81	1.12	0.97	1.01	1.07	0.74	0.68	0.61		+1.1%
	Capex	(0.04)	(0.01)	(0.09)	(0.08)	(0.06)	(0.85)	(1.81)	(0.92)	(0.44)	(0.01)	(0.03)		(11.4%)
	Free cash flow	0.57	0.80	0.63	0.72	1.06	0.12	(0.79)	0.15	0.30	0.66	0.58		+1.7%
	Book value	(1.90)	(1.77)	(1.19)	(0.89)	(0.35)	0.51	(0.18)	(1.32)	(1.63)	(2.31)	(2.03)		+2.2%
	Shares, m	8	7	7	8	8	8	8	8	8	8	8		(0.1%)
Valuation, ×
Valuation, ×	P/E	0.00	24.42	0.00	26.32	15.96	47.62	12.85	0.00	170.80	0.00	0.00		29.8
	P/S	1.49	2.24	1.87	1.85	1.82	3.49	1.22	1.42	2.17	1.02	1.29		1.9
	P/B	0.00	0.00	0.00	0.00	0.00	24.07	0.00	0.00	0.00	0.00	0.00		2.4
	EV/Sales	1.65	2.19	1.97	1.80	1.68	3.30	1.52	1.70	2.43	1.24	1.46		1.9
	EV/FCF	8.22	9.88	12.28	10.54	6.53	97.67	(6.86)	41.61	36.33	10.08	14.28		22.6
Cash, $m
Cash, $m	Operating cash flow	5	6	5	6	8	8	9	9	6	5	5		+1.0%
	Capex	0	0	(1)	(1)	0	(7)	(15)	(8)	(4)	0	0		(11.4%)
	Free cash flow	5	6	5	6	8	1	(7)	1	2	5	5		+1.6%
Balance, $m
Balance, $m	Working capital	(4)	(1)	(1)	0	2	(5)	(10)	(11)	(9)	(8)	(2)		+7.8%
	Net debt	6	1	6	2	(4)	(6)	9	9	8	7	4		+2.6%
	Shareholders’ equity	(15)	(13)	(9)	(7)	(3)	4	(2)	(11)	(13)	(19)	(16)		+2.1%
Returns, %
Returns, %	ROA	(6.77)	10.66	(2.58)	5.37	8.14	3.90	4.41	(15.10)	0.64	(3.84)	(3.10)		+2.9 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	33.07	0.00	0.00	0.00	0.00		0.0 pt
	ROE	12.96	(16.59)	7.98	(28.89)	(75.37)	274.29	208.38	151.67	(3.32)	15.27	12.46		+2.3 pt
People
People	Employees	75	81	101	97	98	93	88	88	86	76	—		+0.1%
	Revenue/emp, $m	0.31	0.31	0.29	0.33	0.32	0.31	0.34	0.36	0.37	0.42	—		+3.4%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Nov 2025 · latest quarter Aug 2026 · fundamentals updated 2 Nov 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
JYNT The Joint Corp.	$104.2M	25.5×	20.1×	+14.41% (above 0%: growing)	+400.00% (above 0%: growing)	+432.31% (above 0%: growing)	83.68%	(2.43%)	Compare
AIRS AirSculpt Technologies, Inc.	$103.8M	— (loss-making)	— (loss-making)	−8.71% (below 0%: shrinking)	n/m	−813.83% (below 0%: shrinking)	0.00%	0.00%	Compare
PARK Park Dental Partners, Inc.	$95.8M	— (loss-making)	—	+12.15% (above 0%: growing)	−65.84% (below 0%: shrinking)	−34.78% (below 0%: shrinking)	14.37%	1.90%	Compare
BMGL Basel Medical Group Ltd	$70.5M	—	—	—	—	—	—	—	Compare
CCEL Cryo-Cell International Inc.	$39.9M	— (loss-making)	65.1×	−0.02% (below 0%: shrinking)	+77.78% (above 0%: growing)	−58.37% (below 0%: shrinking)	79.38%	28.04%
BTMD biote Corp.	$37.4M	6.6×	— (loss-making)	−9.48% (below 0%: shrinking)	n/m	−174.16% (below 0%: shrinking)	65.38%	(7.93%)	Compare
PIII P3 Health Partners Inc.	$28.1M	— (loss-making)	—	+8.60% (above 0%: growing)	n/m	−272.24% (below 0%: shrinking)	22.26%	10.67%	Compare
DCGO DocGo Inc.	$24.1M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−132.28% (below 0%: shrinking)	30.52%	(24.41%)	Compare
CCM Concord Medical Services Holdings Limited	$10.0M	— (loss-making)	— (loss-making)	+37.65% (above 0%: growing)	n/m	−281.45% (below 0%: shrinking)	(13.15%)	0.00%	Compare
Median of peers	$53.9M	—	—	+8.60%	—	−174.16%	22.26%	0.00%

All 51 Medical Care Facilities stocks →

Pay and ownership Proxy statement filed 13 October 2026

Ownership

Directors and executive officers, together 39.93%

David Portnoy 23.48%

Mark Portnoy 13.14%

Camac Partners, LLC 6.83%

Adam Fleishman Trustee of the Adam Fleishman Trust dated April 6.31%

Duke University 5.08%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement